Insider Selling: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells 38,228 Shares of Stock

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) Director David Hallal sold 38,228 shares of the firm's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $10.24, for a total value of $391,454.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Hallal also recently made the following trade(s):

• On Thursday, June 5th, David Hallal sold 38,227 shares of iTeos Therapeutics stock. The stock was sold at an average price of $10.15, for a total value of $388,004.05.

iTeos Therapeutics Stock Performance

ITOS traded down $0.13 during trading on Monday, hitting $10.04. 1,104,582 shares of the stock were exchanged, compared to its average volume of 661,405. The firm has a market cap of $384.27 million, a price-to-earnings ratio of -3.19 and a beta of 1.51. iTeos Therapeutics, Inc. has a 1 year low of $4.80 and a 1 year high of $18.13. The firm has a 50 day simple moving average of $7.38 and a 200 day simple moving average of $7.47.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.14. As a group, equities analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On iTeos Therapeutics

Several hedge funds have recently made changes to their positions in the company. Strs Ohio acquired a new position in shares of iTeos Therapeutics during the 1st quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of iTeos Therapeutics during the fourth quarter valued at approximately $42,000. CWM LLC raised its holdings in shares of iTeos Therapeutics by 428.7% during the first quarter. CWM LLC now owns 8,554 shares of the company's stock valued at $51,000 after buying an additional 6,936 shares during the last quarter. Paloma Partners Management Co bought a new stake in iTeos Therapeutics during the first quarter worth approximately $65,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in iTeos Therapeutics in the first quarter worth approximately $67,000. Hedge funds and other institutional investors own 97.16% of the company's stock.

Wall Street Analysts Forecast Growth

ITOS has been the topic of several research reports. Piper Sandler restated an "overweight" rating and set a $12.00 price target (down from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Leerink Partners reissued a "market perform" rating and set a $9.00 price objective (down from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Wedbush lowered iTeos Therapeutics from an "outperform" rating to a "neutral" rating and boosted their price objective for the company from $10.00 to $12.00 in a research report on Wednesday, May 28th. Raymond James set a $12.00 target price on iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, Leerink Partnrs cut iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, iTeos Therapeutics currently has a consensus rating of "Hold" and an average price target of $15.86.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.